News / Taiwan / cnyes
Taiwan Index Rebalancing: Alvotech Joins Taiwan 50, Alchip-KY Downgraded to Mid-Cap 100
Electronic Technology · Semiconductors · cnyes · 2026-09-04
1301, 2379, 2615, 3006, 3189, 3481, 3661, 6446
The TWSE and FTSE Russell have announced the Q3 2026 index review, featuring the promotion of PharmaEssentia to the Taiwan 50 and the reclassification of Alchip-KY to the Mid-Cap 100.
What Happened
Index Review Results: The Taiwan Stock Exchange and FTSE Russell have finalized the Q3 2026 index review, with PharmaEssentia entering the Taiwan 50 index due to its significant market capitalization growth. Conversely, Alchip-KY has been removed from the Taiwan 50 and reclassified into the Taiwan Mid-Cap 100 index, with changes effective after the market close on September 18.
Mid-Cap 100 Adjustments: The Taiwan Mid-Cap 100 index will see several changes, including the addition of Alchip-KY, Crystalwise, and other innovative biotech firms. Stocks such as Taiwan Elite, Nuvoton, PharmaEssentia, and Tatung have been removed from the index, reflecting the evolving landscape of the mid-cap segment.
High Dividend Index: While the Taiwan High Dividend Index remains unchanged in terms of constituent stocks, it will undergo a five-day weight transition period starting September 21. Investors should monitor the impact of these weight adjustments on ETFs tracking the index as funds rebalance their portfolios.
Market Implications: The exchange has advised investors that the reserve lists are now effective, with replacements to be made if current constituents are removed. Given the anticipated rebalancing by passive funds and ETFs, market participants should prepare for potential volatility and liquidity shifts in the affected stocks.